Markets.News

ALNY  ALNYLAM PHARMACEUTICALS INC

+ add to watchlist

$453.37

alnylam is developing an entirely new class of innovative medicines based on a breakthrough discovery in biology known as rna interference, or rnai. with rnai technology, we have the opportunity to treat disease and impact the lives of patients in a fundamentally new way by silencing disease-causing genes upstream of today's medicines.

Mkt Cap: $58.65B

52 Week High: $469.81

P/E: -462.35

52 Week Low: $205.87

Dividend: $0.00

Shares Outstanding: 131.08M

This news is delayed by 15 minutes, sign up now to get live news & full features.